Angelo Reggiani Selected Research

muramyl- NAc- (pentapeptide)pyrophosphoryl- undecaprenol

11/2021

Understanding the Mechanism of Action of NAI-112, a Lanthipeptide with Potent Antinociceptive Activity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Angelo Reggiani Research Topics

Disease

14	Pain (Aches) 07/2022 - 02/2005
10	Hyperalgesia 07/2022 - 10/2003
6	Neuralgia (Stump Neuralgia) 11/2021 - 02/2005
5	Inflammation (Inflammations) 07/2022 - 05/2012
5	Chronic Pain 12/2012 - 02/2005
4	Migraine Disorders (Migraine) 07/2022 - 01/2020
3	Alzheimer Disease (Alzheimer's Disease) 03/2013 - 11/2012
2	Fragile X Syndrome (Martin Bell Syndrome) 01/2022 - 01/2021
2	Bipolar Disorder (Manic Depressive Psychosis) 08/2020 - 11/2015
2	Mood Disorders (Mood Disorder) 05/2020 - 11/2015
2	Parkinson Disease (Parkinson's Disease) 01/2019 - 07/2009
2	Amnesia (Dissociative Amnesia) 01/2013 - 01/2012
2	Cognitive Dysfunction 01/2013 - 01/2012
2	Mental Disorders (Mental Disorder) 07/2009 - 04/2005
2	Peripheral Nervous System Diseases (PNS Diseases) 12/2005 - 11/2005
1	Infections 01/2022
1	Multiple Sclerosis 10/2021
1	Neurodevelopmental Disorders 01/2021
1	Intellectual Disability (Idiocy) 01/2021
1	Mania (Manias) 05/2020
1	Nociceptive Pain 02/2014
1	Peripheral Nerve Injuries 05/2012
1	Arthritis (Polyarthritis) 05/2012
1	Dyskinesias (Dyskinesia) 07/2009

Drug/Important Bio-Agent (IBA)

6	metabotropic glutamate receptor type 1IBA 12/2012 - 04/2005
4	Nitroglycerin (Dynamite)FDA LinkGeneric 07/2022 - 01/2020
4	Formaldehyde (Formol)FDA Link 01/2021 - 04/2005
3	LipidsIBA 07/2022 - 08/2015
3	EndocannabinoidsIBA 07/2022 - 01/2021
3	Analgesics (Analgesic Drugs)IBA 11/2021 - 11/2011
3	N-acylethanolaminesIBA 10/2021 - 03/2013
3	AcidsIBA 10/2021 - 03/2013
3	amidaseIBA 10/2021 - 03/2013
3	Pharmaceutical PreparationsIBA 01/2021 - 04/2009
3	URB937IBA 01/2021 - 05/2012
3	anandamide (arachidonylethanolamide)IBA 01/2021 - 11/2011
3	IndazolesIBA 08/2020 - 11/2015
3	Memantine (Namenda)FDA Link 03/2013 - 01/2012
2	cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597)IBA 07/2022 - 01/2020
2	CytokinesIBA 07/2022 - 01/2021
2	Peptides (Polypeptides)IBA 07/2022 - 01/2013
2	fatty-acid amide hydrolase (fatty acid amide hydrolase)IBA 07/2022 - 01/2021
2	EnzymesIBA 01/2022 - 01/2021
2	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2021 - 11/2011
2	palmidrolIBA 01/2021 - 08/2015
2	Glycogen Synthase Kinase 3IBA 08/2020 - 05/2020
2	Adenosine Triphosphate (ATP)IBA 08/2020 - 11/2015
2	Glycogen Synthase KinasesIBA 05/2020 - 11/2015
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 08/2015 - 03/2013
2	5-phenylpentyl N- ((2S,3R)- 2- methyl- 4- oxo- oxetan- 3- yl)carbamateIBA 09/2013 - 03/2013
2	CarrageenanIBA 03/2013 - 05/2012
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 03/2013 - 11/2003
2	Scopolamine (Hyoscine)FDA Link 01/2013 - 01/2012
2	Galantamine (Galanthamine)FDA LinkGeneric 11/2012 - 01/2012
2	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA 11/2007 - 04/2005
1	Interleukin-1beta (Interleukin 1 beta)IBA 07/2022
1	Substance PIBA 07/2022
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2022
1	Calcitonin Gene-Related PeptideIBA 07/2022
1	CarbamatesIBA 07/2022
1	AmidesIBA 07/2022
1	Nitric Oxide Synthase Type I (Neuronal Nitric Oxide Synthase)IBA 07/2022
1	Angiotensin-Converting Enzyme 2IBA 01/2022
1	Glycoproteins (Glycoprotein)IBA 01/2022
1	lysophosphatidic acidIBA 11/2021
1	Phosphates (Orthophosphate)IBA 11/2021
1	Peptidoglycan (Murein)IBA 11/2021
1	muramyl- NAc- (pentapeptide)pyrophosphoryl- undecaprenolIBA 11/2021
1	Phosphatidic Acids (Phosphatidic Acid)IBA 11/2021
1	iodopravadoline (AM 630)IBA 01/2021
1	AM 251 (AM251)IBA 01/2021
1	NeuropeptidesIBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 01/2021
1	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 01/2021
1	Fragile X Mental Retardation ProteinIBA 01/2021
1	Proto-Oncogene Proteins c-fos (FRAs)IBA 01/2020
1	EthanolaminesIBA 01/2019
1	Phosphatidylethanolamines (Cephalins)IBA 01/2019
1	N-(4-aminophenethyl)spiroperidol (NAPS)IBA 01/2019
1	carbamic acid (ammonium carbamate)IBA 03/2016
1	Glycogen Synthase (Synthase I)IBA 11/2015
1	Fatty Acids (Saturated Fatty Acids)IBA 08/2015
1	oleoylethanolamideIBA 08/2015
1	N-Methylaspartate (NMDA)IBA 03/2013
1	Cholinesterase Inhibitors (Anticholinesterases)IBA 03/2013
1	GW 6471IBA 03/2013
1	Nootropic Agents (Nootropics)IBA 01/2013
1	Amyloid beta-PeptidesIBA 01/2013
1	memoquinIBA 01/2013
1	Gabapentin (Neurontin)FDA LinkGeneric 05/2012
1	Indomethacin (Indometacin)FDA LinkGeneric 05/2012
1	Dexamethasone (Maxidex)FDA LinkGeneric 05/2012
1	Freund's AdjuvantIBA 05/2012
1	phthalazineIBA 11/2011
1	AminesIBA 07/2009
1	2- (2- furanyl)- 7- (2- (4- (4- (2- methoxyethoxy)phenyl)- 1- piperazinyl)ethyl)- 7H- pyrazolo(4,3- e)(1,2,4)triazolo(1,5- c)pyrimidine- 5- amineIBA 07/2009
1	(7- (2- (4- difluorophenyl)- 1- piperazinyl)ethyl)- 2- (2- furanyl)- 7H- pyrazolo(4,3- e)(1,2,4)triazolo(1,5- c)pyrimidin- 5- amineIBA 07/2009
1	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 07/2009

Therapy/Procedure

7	Ligation 03/2013 - 02/2005
2	Topical Administration 09/2013 - 03/2013